![]() |
市場調查報告書
商品編碼
1518566
2024-2032 年麻醉二氧化碳吸收劑市場報告(按產品(鈉石灰、Medisorb、Dragersorb、Amsorb、Litholyme 等)、類型(高級、傳統)、最終用戶(醫院、診所等)和地區Anesthesia CO2 Absorbent Market Report by Product (Soda Lime, Medisorb, Dragersorb, Amsorb, Litholyme, and Others), Type (Premium, Traditional), End User (Hospitals, Clinics, and Others), and Region 2024-2032 |
IMARC Group年,全球麻醉二氧化碳吸收劑市場規模達到7,850萬美元。
麻醉二氧化碳吸收劑是麻醉一次性用品中的一個特殊部分,主要用於吸收麻醉過程中呼出的氣體。這些吸收劑配方由強氫氧化鉀和氫氧化鈉鹼組成,有助於將麻醉分子中的不穩定質子轉化為一氧化碳 (CO),有助於最大限度地減少麻醉廢物。由麻醉吸收劑組成的二氧化碳吸收裝置被併入麻醉機的呼吸裝置中,位於環形迴路的吸氣肢和呼氣肢之間。它們的功能是將新鮮氣體的流量限制在閉路條件下,並允許呼出的麻醉劑被重新吸入。然而,一氧化碳(CO)的產生會對患者的健康造成危害。某些二氧化碳吸收劑不含氫氧化鉀和氫氧化鈉,因此不會透過與吸入劑反應產生一氧化碳。
這個市場主要是由心臟病、神經系統疾病、呼吸系統疾病和糖尿病等慢性病發病率上升所推動的。同時,越來越多的老年人口容易患上最終需要手術干預的疾病,這為市場提供了巨大的推動力。除此之外,隨著眾多醫療機構進行的手術數量不斷增加,對麻醉一次性用品的需求大幅增加,從而促進了產品在全球的採用。有關整個醫療保健行業麻醉藥品和設備使用的各種嚴格的政府指南和安全參數進一步推動了產品需求。除此之外,用於開發先進二氧化碳吸收配方的研發(R&D)活動的投資不斷增加以及醫療保健支出的不斷增加也推動了市場成長。
The global anesthesia CO2 absorbent market size reached US$ 78.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 129.0 Million by 2032, exhibiting a growth rate (CAGR) of 5.6% during 2024-2032.
Anesthesia CO2 absorbent is a specific segment within the anesthesia disposables, which is primarily used to absorb exhaled gases during anesthesia administration. Consisting of strong potassium hydroxide and sodium hydroxide bases that help obtain labile protons from anesthetic molecules to carbon monoxide (CO), these absorbent formulations are instrumental in minimizing anesthetic wastes. The CO2 absorber devices consisting of anesthesia absorbents are incorporated into the ventilatory apparatus of the anesthesia machine between the inspiratory and expiratory limbs of a circle circuit. They function by limiting the flow of fresh gas to closed-circuit conditions and allowing exhaled anesthetic agents to be rebreathed. However, the production of carbon monoxide (CO) can cause health hazards to patients. Certain CO2 absorbents do not contain potassium hydroxide, and sodium hydroxide and consequently do not produce carbon monoxide by reacting with inhaled agents.
The market is primarily driven by the rising incidences of chronic conditions, such as cardiac disorders, neurological conditions, respiratory diseases, and diabetes. Along with this, the growing geriatric population that is susceptible to developing medical conditions ultimately requiring surgical intervention is providing a significant boost to the market. Besides this, with the rising number of surgeries conducted across numerous healthcare settings, there has been a considerable rise in the demand for anesthesia disposables, thereby contributing to the product adoption across the globe. Various stringent government guidelines and safety parameters regarding the usage of anesthetic drugs and equipment across the healthcare sector are further propelling the product demand. In addition to this, the increasing investments in the research and development (R&D) activities for developing advanced CO2 absorbing formulations and the expanding healthcare expenditure are also providing an impetus to the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global anesthesia CO2 absorbent market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, type and end user.
Soda Lime
Medisorb
Dragersorb
Amsorb
Litholyme
Others
Premium
Traditional
Hospitals
Clinics
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Armstrong Medical Ltd. (Eakin Healthcare Group Ltd), Atrasorb, Dragerwerk AG & Co. KGaA, General Electric Company, Intersurgical Ltd., Lowenstein Medical SE & Co. KG, Micropore Inc., Molecular Products Group plc (Filtration Group Corporation) and Smiths Medical Inc. (ICU Medical Inc.).